Drug intelligence / Profile preview

influenza virus vaccine inactivated

Development stage: Approved
Lead developer: Merck
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Inactivated influenza vaccines are noninfectious, sterile suspensions of suitably inactivated influenza virus types A and B subunits representing influenza strains likely to circulate during the upcoming flu season. These vaccines are modified annually to include the most prevalent strains (usually 2 strains of influenza A and 1 or 2 strains of influenza B). The vaccine stimulates active immunity to influenza strains contained in the vaccine, helping prevent influenza (flu). It cannot cause the disease as it contains virus that is not active.

Brand names: AfluriaFluadFluarixFlucelvaxFlulavalFluzoneFluzone High-Dose
Other names: IIVInactivated influenza vaccine

Beyond the preview

Go deeper on influenza virus vaccine inactivated.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on influenza virus vaccine inactivated.

Explore the full profile